CD56 PerCP-Cyanine5.5
Catalog #
Size
| Conjugation | PerCP-Cyanine5.5 |
|---|---|
| Antigen | CD56 |
| Clone | 5.1H11 |
| Isotype | IgG1, k |
| Applications | FC |
| Reactivity | Human |
| Host | Mouse |
| Clonality | Monoclonal |
| Primary/Secondary | Primary |
| Immunogen | Human myotube cells |
| Format | 0.09% NaN3, 0.2% BSA (w/v), PBS pH 7.2 |
| Storage | 2-8°C |
| Excitation Laser | Blue (488nm) |
| Status | ASR |
Description:
The clone 5.1H11, a mouse monoclonal antibody, selectively binds to the human 140-kDa glycoprotein, an isoform of neural cell adhesion molecule (NCAM) known as CD56. It is a member of Immunoglobulin (Ig) superfamily. CD56 and CD16 expressing lymphocytes are primarily considered as human NK cells and NK-T cells. A subset of CD56+ NK cells plays a unique functional role in the innate immune response as the primary source of NK cell–derived immunoregulatory cytokines, regulated in part by differential monokine production. CD56 is expressed in normal and as well as neoplastic human neuroendocrine tissues, certain large granular lymphocyte (LGL) leukemias, small-cell lung carcinomas, neuronal derived tumors, myelomas, and myeloid leukemias. Additionally, increased CD56+ lymphocyte subsets in peripheral blood are a significant predictive or prognostic factor in metastatic breast cancer.
The clone 5.1H11, a mouse monoclonal antibody, selectively binds to the human 140-kDa glycoprotein, an isoform of neural cell adhesion molecule (NCAM) known as CD56. It is a member of Immunoglobulin (Ig) superfamily. CD56 and CD16 expressing lymphocytes are primarily considered as human NK cells and NK-T cells. A subset of CD56+ NK cells plays a unique functional role in the innate immune response as the primary source of NK cell–derived immunoregulatory cytokines, regulated in part by differential monokine production. CD56 is expressed in normal and as well as neoplastic human neuroendocrine tissues, certain large granular lymphocyte (LGL) leukemias, small-cell lung carcinomas, neuronal derived tumors, myelomas, and myeloid leukemias. Additionally, increased CD56+ lymphocyte subsets in peripheral blood are a significant predictive or prognostic factor in metastatic breast cancer.